课题基金 / 基金详情

CARRIERS FOR MEMBRANE TRANSPORT OF AIDS-TARGETED DRUGS

CARRIERS FOR MEMBRANE TRANSPORT OF AIDS-TARGETED DRUGS
艾滋病药物的膜运输载体
批准号:
3304379
负责人:
JULIUS REBEK
金额:
$19.01万
依托单位国家:
美国
项目类别:
财政年份:
1990
资助国家:
美国
项目状态:
已结题
起止时间:
1990-06-06 至 1993-05-31

项目摘要

项目成果

JULIUS REBEK的其他基金

相关文献

中文摘要
翻译
艾滋病,在过去的八年里已导致大约65,000名美国人死亡 Years的特点是免疫系统严重失衡,由 人类免疫缺陷病毒感染辅助性/诱导性T细胞 爱滋病毒。这种逆转录病毒通过DNA中间体进行复制, HIV编码的DNA催化合成与病毒DNA互补的DNA 聚合酶,逆转录酶,抑制的主要候选者 针对艾滋病的药物。2‘,3’-二脱氧核苷,如3‘-叠氮-2’,3‘- 二脱氧硫亚胺(AZT)是一种有效的HIV逆转底物抑制剂 转录酶,以及它们的整合导致DNA链终止和 抑制病毒复制。对于细胞内激活, 双脱氧核苷必须被细胞核苷酶磷酸化以 生成活性5‘-三磷酸酯。 这一应用推动了选择性合成载体的发展 用于5‘-磷酸化艾滋病药物跨细胞膜的运输。 新的载体结合了立体电子效应的最新进展。 和分子形状。承运人的具体识别要素包括 互补的氢键边和疏水位置(芳香族 片状或非极性环状空腔)用于嘌呤或嘧啶碱, 和阳离子位点结合到磷酸功能上。普通合成 概述的协议预计将允许开发特定的 广泛的双脱氧核苷-5‘-的载体- 三磷酸盐穿过细胞膜。 识别的选择性将在核磁共振滴定中定义, 萃取实验和微量热法测量。交通工具 单核苷-5‘-三磷酸和寡核苷酸的效率 通过液体有机膜应提供一种手段,通过它 新受体的载体特性可以得到改进。所描述的 这些项目旨在为高效运输提供一个通用的解决方案 这些化合物跨越细胞膜。这可能会打开新的视角 艾滋病治疗和扩大考虑的候选药物的数量 与这种致命的疾病作斗争。
英文摘要
AIDS, which has killed approximately 65,000 Americans over the past eight years is characterized by a severe imbalance of the immune system caused by the infection of helper/inducer T cells by the human immunodeficiency virus HIV. This retrovirus replicates through a DNA intermediate, and the synthesis of DNA complementary to viral DNA is catalyzed by a HIV-encoded polymerase, reverse transcriptase, a prime candidate for inhibition by AIDS-targeted drugs. 2',3'-Dideoxynucleosides like 3'-azido-2',3'- dideoxythimidine (AZT) are efficient substrate inhibitors of HIV reverse transcriptase, and their incorporation leads to DNA chain termination and inhibition of viral replication. For intracellular activation, the dideoxynucleosides must be phosphorylated by cellular nucleoside kinases to yield the active 5'-triphosphates. This application proposes the development of selective synthetic carriers for the transport of 5'-phosphorylated AIDS drugs across cell membranes. The new carriers incorporate recent advances in stereoelectronic effects and molecular shape. Specific recognition elements of the carriers include complementary hydrogen bonding edges and a hydrophobic site (an aromatic sheet or an apolar cyclophane cavity) for the purine or pyrimidine base, and cationic sites to bind to the phosphate functions. General synthetic protocols outlined are expected to allow the development of specific carriers for the delivery of a wide range of dideoxynucleoside-5'- triphosphates across membranes. The selectivity in recognition will be defined in NMR titrations, extraction experiments, and microcalorimetric measurements. The transport efficiencies of mononucleoside-5'-triphosphates and oligonucleotides through liquid organic membranes should provide a means by which the carrier properties of the new receptors could be refined. The described projects intend to provide a general solution to the efficient transport of these compounds across cell membranes. This may open new perspectives in AIDS therapy and widen the number of drug candidates to be considered for fighting this deadly disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Synthetic TIR Domain Mimetics as a Novel Strategy for Intervention in Sepsis
  • 批准号:
    8128306
  • 项目类别:
  • 资助金额:
    $39.02万
  • 财政年份:
    2010
  • 负责人:
    JULIUS REBEK
  • 依托单位:
ASSEMBLY OF SELF-COMPLEMENTARY STRUCTURES
ASSEMBLIES OF SELF COMPLEMENTARY STRUCTURES
  • 批准号:
    6468788
  • 项目类别:
  • 资助金额:
    $8.71万
  • 财政年份:
    1993
  • 负责人:
    JULIUS REBEK
  • 依托单位:
Assemblies of Self Complementary Structures
  • 批准号:
    6470797
  • 项目类别:
  • 资助金额:
    $37.52万
  • 财政年份:
    1993
  • 负责人:
    JULIUS REBEK
  • 依托单位: